---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037597"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:33:51.407899+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Intellia Q2 net loss $123.7M; advances CRISPR pipeline with Phase 2 enrollment for NTLA-2002 completed

## Summary
- Cash, equivalents and securities $1.1B at June 30, 2023, down from $1.3B at Dec 31, 2022.
- Net loss $123.7M in Q2 2023 vs $100.7M in Q2 2022; R&D expenses rose to $115.3M.
- All patients identified for NTLA-2002 Phase 2 study; pivotal Phase 3 planned for Q3 2024.
- NTLA-2001 IND submission for ATTR-CM expected in September; global pivotal study targeted by year-end 2023.

## SEC filing metadata
- accession: 0000950170-23-037597
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/0000950170-23-037597-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/ntla-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037597
- JSON: https://secwatch.observer/filing/0000950170-23-037597.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037597.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023037597/0000950170-23-037597-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.